Menopause Wearables' Evidence Gap: Sensors Yes, Trials No

Menopause tech now has good sensors and very little proof. Oura and Natural Cycles already offer perimenopause tracking, Apple announced its own for iOS 27 and watchOS 27 in September 2026, and dozens of apps pull in wearable data. But a systematic review posted as a preprint in August 2026 (not yet peer-reviewed) found that only 4 of 80 menopause apps reported published evaluations. For now, treat these products as tools for organizing your records, not as proven ways to detect or treat symptoms.

A ring that logs your skin temperature at night is measuring something real. Whether that tells you anything reliable about perimenopause, and whether acting on it improves symptoms, is a separate question that almost nobody has tested in a trial. Below: what changed, what the evidence shows, and a checklist for judging a product.

Note: This is technology analysis, not medical advice. Perimenopause and menopause symptoms overlap with other conditions, so talk to a clinician about any symptom that worries you.

What changed in menopause tracking in 2025 and 2026?

Three of the biggest consumer platforms moved into this space within about a year:

• Apple (iOS 27 and watchOS 27). On September 9, 2026, Apple announced that "the Health app adds support for perimenopause and menopause" in Cycle Tracking. Users can log whether they are in perimenopause or menopause, track symptoms, and monitor cycles over time. Users age 40 and over can receive a notification "if a deviation in their logged cycle patterns is suggestive of perimenopause," and anyone who logs bleeding after menopause is prompted to speak with their doctor. The fine print in Apple's Apple Watch Series 12 announcement reads: "The Cycle Tracking app should not be used for birth control or to diagnose a health condition." Neither release cites a study behind the menopause features.
• Oura (Menopause Insights). Oura's August 2025 post introduced Menopause Insights, built around the Menopause Impact Scale, which Oura describes as "a research-backed questionnaire developed by Oura" covering 22 symptoms. According to Oura's support page, it is for members aged 35 to 60 with a Gen3 ring or later and an active membership, and it prompts you to retake the questionnaire every 30 days.
• Natural Cycles (NC° Perimenopause). Natural Cycles introduced NC° Perimenopause in October 2025. It offers a stage assessment and tracks symptoms such as hot flashes, brain fog and joint pain, plus triggers like caffeine and alcohol. Its compatible-devices page lists the NC° Band, Oura Ring, Garmin, WHOOP and Apple Watch as temperature sources. WHOOP users need both an NC° and a WHOOP subscription.

The pattern is consistent. Each company reuses sensors it already ships (overnight temperature, heart rate, heart rate variability, sleep) and adds a menopause layer of questionnaires, logging and educational content on top. That is a sensible product decision. It is not the same thing as clinical validation, and none of these companies claims that it is. We covered the fertility side of the same hardware in our guide to women's health wearables. The menopause layer is newer and has much less evidence behind it.

What does the "80 apps, 5% evaluated" review actually say?

The figure comes from "The current state of apps and wearables for supporting peri/menopausal individuals: a systematic review" by Madeleine Sorensen, Stephen Friend, Nina Coslov, Anna Goldenberg, Robin Yang and Sarah Goodday. It was posted on Research Square, whose page carries the notice: "This is a preprint; it has not been peer reviewed by a journal." Europe PMC indexes its first publication date as August 25, 2026, and Research Square lists it as under revision at a journal. The authors acknowledge support from 4YouandMe.

The authors searched Embase, Medline, PubMed, IEEE Xplore, the Apple App Store and Google Play for tools and studies published from 2015 to 2025. Their main findings:

Finding (80 apps reviewed)	Count	Share
Offer symptom tracking	77	96.25%
Offer educational content	53	66.25%
Include AI-driven features	42	52.5%
Offer paid subscription tiers	56	70%
Integrate consumer wearables	22	27.5%
Let you export symptom summaries (e.g. for a clinician)	20	25%
Show third-party ads for menopause products	14	17.5%
Offer interventions	11	13.75%
Report published evaluations	4	5%
Examined long-term or clinically verified outcomes, or a planned trial	2	2.5%

Their conclusion is blunt: the market "has saturated in recent years despite notable gaps in published evidence of user benefit or knowledge of underlying AI decision tools, creating uncertainty in effectiveness." The table shows the imbalance clearly. Far more apps charge a subscription (56) than have published any evaluation (4), and 42 use AI features whose inner workings the review says are poorly documented.

Read the preprint as a well-documented map, not a final verdict: its numbers could change in peer review. Its direction, though, matches what you find when you check individual products.

Which menopause products have published trials?

The published evidence is thin, and most of it tests software or a cooling device rather than sensing. Here is what the review and the underlying papers show, alongside the big-platform features with no published product-specific evaluation.

Product	What it is	Published evidence	Caveats
Caria (Chorus Health)	Symptom tracking app with a CBT program	6-week randomized trial, 149 women (112 app, 37 web-education control); lower hot flash severity in the app arm	Sponsored by Chorus Health; two authors employed by the company; short follow-up
Health & Her	Stage-specific app with CBT exercises and manual symptom logging	2-month cohort study, 1,900 users; more engagement associated with larger symptom reductions	No control group, so it shows association, not cause; authors include company staff and the CEO
Embr Wave	Wrist-worn warming/cooling device (relief, not tracking)	Exploratory 4-week randomized crossover of a wrist warming/cooling device, which the review links to Embr Wave; 39 women aged 45–58; fewer reported hot flashes interfering with sleep (90% vs 70%)	Small, self-reported outcomes; the authors call it exploratory
Oura Menopause Insights	Ring sensors plus the Menopause Impact Scale questionnaire	None product-specific; the preprint says menopause-specific algorithms are "emerging, not currently validated"	Oura says its 2024 Perimenopause Report analyzed data from over 100,000 members. That is observational data, not a trial.
NC° Perimenopause	Stage assessment and symptom tracking with wearable temperature	None for the perimenopause mode, per the preprint	The birth-control app was granted FDA De Novo authorization in August 2018; the perimenopause mode is described as "not a diagnosis"
Apple Cycle Tracking (iOS 27)	Perimenopause/menopause logging and cycle-deviation notifications	No study cited in Apple's announcement	Apple says Cycle Tracking should not be used "to diagnose a health condition"
Peri (identifyHer)	Body-worn biosensor that passively tracks hot flashes and night sweats	None cited on the maker's site; the preprint says peer-reviewed validation is "not yet published"	A dedicated sensor, but no public accuracy data

Two things stand out. First, the products with trials are mostly software that changes behavior, such as CBT programs, or hardware that treats a symptom, such as a cooling band. The products that sense perimenopause, which is the main pitch of the wearable companies, have no published product-specific validation. Second, the Caria and Health & Her studies were sponsored or co-authored by the companies behind the apps, and one author of the cooling-device study worked at Johnson & Johnson Consumer Inc. That is normal in digital health and does not make a result wrong, but it is one more reason to want independent replication.

Embr Wave shows how marketing can run ahead of the papers. Its product page says participants in clinical studies "saw over 2x better control over hot flashes and up to 28% fewer daytime and nighttime hot flashes." The peer-reviewed crossover study in the table measured sleep interference and perceived control. If you want to check the page's specific figures, look for the study behind each one.

Why are there so many sensors and so few trials?

The gap is not an accident. It follows from how these products are built and sold.

Reusing sensors is cheap; validating a new use is expensive. Temperature sensing in rings and watches was built for sleep and cycle tracking. Adding a menopause screen, questionnaire and educational content to an existing app costs little. Running a controlled study that compares sensor readings with clinical assessments across different perimenopause stages costs a lot and takes years.

"Wellness" framing avoids the need for regulatory proof. Natural Cycles is the useful contrast. Its contraceptive algorithm went through FDA's De Novo process in 2018. The review calls it "the only peri/menopause-focused tool in our sample whose core technology has undergone formal regulatory review." Its perimenopause mode, like Apple's and Oura's features, is presented as information and insight rather than a diagnosis. That framing is honest, and it also means no regulator has checked the menopause-specific claims.

The detection science is early. Research shows hot flashes can in principle be detected from sensor data. A 2025 study in Psychophysiology (Naghavi et al.) measured skin conductance on the lateral torso of 62 peri- or postmenopausal women. The best model identified 82% of hot flash events, on average 17 seconds before onset, with a false-positive rate under 2%. That is a promising feasibility result. It also used a torso sensor rather than a wrist or finger, was a research model rather than a shipping feature, and several authors were current or former Embr Labs employees or consultants. It shows what might be possible, not what your ring does today.

Subscription economics reward engagement, not outcomes. With 70% of apps in the review offering paid tiers, the business measure is retention. Logging streaks and personalized insights keep people subscribed whether or not symptoms improve. For the same trade-offs in adjacent categories, see our comparisons of mood-tracking apps and consumer sleep trackers.

What is menopause tracking actually good for right now?

A lack of trials does not make these tools useless. It narrows what you should expect from them.

• A structured symptom diary. Symptom tracking is the one feature nearly every app offers (77 of 80 in the review). A dated log of hot flashes, sleep, mood and cycle changes gives you and a clinician a clearer picture than memory alone.
• Something to bring to an appointment. Apple's cycle-deviation notification is explicitly designed to prompt a conversation with your doctor. A quarter of the apps in the review let you export summaries. Use that feature if it exists.
• Trends in your own data. Overnight temperature and heart rate variability trends can show when your sleep or recovery changes. They cannot, on current evidence, confirm what stage of the transition you are in.

What it is not good for: diagnosing perimenopause, confirming a stage, or replacing clinical evaluation of symptoms such as bleeding after menopause. Apple itself routes that last case straight to a doctor.

How should you evaluate a menopause app or wearable?

Use these seven questions. They take about ten minutes and apply to any product in this category.

1. What exactly does it claim to do? Tracking, detecting and treating are different claims that need different evidence. A symptom diary needs little proof. A claim to "detect" hot flashes or "identify your stage" needs published accuracy data.
2. Is there a published study of this product? Look for a paper in a peer-reviewed journal (PubMed is free to search). Research about menopause in general, or about the sensor category, is not evidence for the specific product.
3. Did the study have a control group? A randomized comparison (like the Caria trial) tells you more than a before-and-after study of engaged users (like the Health & Her cohort), where people who stick with an app may differ from those who drop out.
4. Who funded it and how long did it run? Company funding is common, so check for it rather than assuming. A six-week result says little about what happens with long-term use.
5. What does the fine print say? Phrases like "not a diagnosis" or "should not be used to diagnose a health condition" tell you how the company itself classifies the product.
6. Can you export your data? If the main value is a symptom record, you should be able to take it to a clinician and keep it if you cancel.
7. How does it make money? Subscriptions and ads for supplements or therapies inside a symptom app give the company a reason to promote products. Weigh its recommendations with that in mind.

For comparison, wrist ECG features from Apple, Withings, Samsung and Google are FDA-cleared. That is roughly the evidence standard a "detects your perimenopause stage" claim would need to meet. No menopause wearable has reached it yet.

What would close the evidence gap?

These companies already hold the data. What is missing is the right studies: sensor readings validated against clinical assessment with published accuracy, controlled trials that follow users for months rather than weeks, and replication by researchers without a financial stake. Things to watch: whether the Sorensen et al. review passes peer review, whether Oura, Apple or Natural Cycles publish validation for their menopause features, and whether any company takes a menopause-detection claim through FDA review, as Natural Cycles did for contraception. Until then, use these tools to keep better records and to start a conversation with your doctor, not to settle a medical question.

Frequently Asked Questions

Can a wearable tell me if I am in perimenopause?

Not reliably, on current published evidence. Oura and Natural Cycles offer perimenopause tracking and Apple has announced it for iOS 27, but none has published product-specific validation showing its sensors can identify perimenopause or its stage. Apple's notification flags cycle patterns "suggestive of perimenopause" so you can talk to your doctor, and it says Cycle Tracking should not be used to diagnose a health condition.

Is the "only 5% of menopause apps are evaluated" figure reliable?

It comes from a systematic review by Sorensen and colleagues posted on Research Square in August 2026. It is a preprint, which means it has not yet been peer-reviewed by a journal, and it is listed as under revision. It found 4 of 80 apps reported published evaluations. Treat the exact numbers as provisional, though the overall direction matches product-by-product checks.

Which menopause apps have clinical trial evidence?

Caria has a 6-week randomized controlled trial of 149 women published in JMIR mHealth and uHealth in 2025, which found lower hot flash severity than a web-education control. Health & Her has a 1,900-user cohort study without a control group. Embr Wave, a cooling wristband, has a small exploratory crossover study. The Caria and Health & Her studies were sponsored or co-authored by the app makers.

Is Natural Cycles' perimenopause mode FDA-cleared?

No. Natural Cycles' birth-control app was granted FDA De Novo authorization in August 2018. Its perimenopause mode is a separate feature that the company describes as wellness insights and information, stating "It's not a diagnosis." The FDA's review of the contraceptive algorithm does not extend to perimenopause claims.

Should I pay for a menopause tracking subscription?

Only if you value the symptom diary and data export on their own, because that is the part the evidence supports. Check whether the product has a published study, whether you can export your data, and whether the app shows ads for supplements or therapies. Do not rely on any app to diagnose symptoms. Discuss them with a clinician.